Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharyn D Baker

Showing results (121-130 of 166) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancerChristopher J Sweeney, Chris H Takimoto, Jane E Latz, et al.
Kidney International|June 17, 2026
Genome-wide Screen Identifies Peroxisomal Role in APOL1 PodocytopathyJiyoung Kim, Isaac Z Karel, Huijuan Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Pharmacokinetics and toxicity of weekly docetaxel in older patientsArti Hurria, Mark T Fleming, Sharyn D Baker, et al.
Breast Cancer Research and Treatment|February 26, 2011
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancerRoisin M Connolly, Michelle A Rudek, Elizabeth Garrett-Mayer, et al.
Cancer Research|February 18, 2017
OCTN1 Is a High-Affinity Carrier of Nucleoside AnaloguesChristina D Drenberg, Alice A Gibson, Stanley B Pounds, et al.
Pediatric Blood & Cancer|April 15, 2017
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03)Todd M Cooper, Edward Allan Racela Sison, Sharyn D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancerDana Rathkopf, Michael A Carducci, Michael J Morris, et al.
Investigational New Drugs|May 19, 2019
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AMLJae Yoon Jeon, Qiuhong Zhao, Daelynn R Buelow, et al.
The Journal of Clinical Investigation|December 12, 2017
Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemiaJolieke G van Oosterwijk, Daelynn R Buelow, Christina D Drenberg, et al.
Pharmacogenomics|April 1, 2011
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypesJatinder K Lamba, Kristine R Crews, Stanley B Pounds, et al.
Pageof 17

Showing results (121-130 of 166) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancerChristopher J Sweeney, Chris H Takimoto, Jane E Latz, et al.
Kidney International|June 17, 2026
Genome-wide Screen Identifies Peroxisomal Role in APOL1 PodocytopathyJiyoung Kim, Isaac Z Karel, Huijuan Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
Pharmacokinetics and toxicity of weekly docetaxel in older patientsArti Hurria, Mark T Fleming, Sharyn D Baker, et al.
Breast Cancer Research and Treatment|February 26, 2011
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancerRoisin M Connolly, Michelle A Rudek, Elizabeth Garrett-Mayer, et al.
Cancer Research|February 18, 2017
OCTN1 Is a High-Affinity Carrier of Nucleoside AnaloguesChristina D Drenberg, Alice A Gibson, Stanley B Pounds, et al.
Pediatric Blood & Cancer|April 15, 2017
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03)Todd M Cooper, Edward Allan Racela Sison, Sharyn D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancerDana Rathkopf, Michael A Carducci, Michael J Morris, et al.
Investigational New Drugs|May 19, 2019
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AMLJae Yoon Jeon, Qiuhong Zhao, Daelynn R Buelow, et al.
The Journal of Clinical Investigation|December 12, 2017
Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemiaJolieke G van Oosterwijk, Daelynn R Buelow, Christina D Drenberg, et al.
Pharmacogenomics|April 1, 2011
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypesJatinder K Lamba, Kristine R Crews, Stanley B Pounds, et al.
Pageof 17